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Abstract
Background: Managing therapy-related side-effects and improving health-related quality of life in patients with
colorectal cancer is still challenging. The need for an effective management of adverse events and unmet supportive
care needs have been widely discussed. In the past decade, interventions by nursing staff gained more and more
importance. Evidence suggests that a majority of patients even in early stages of the disease experience substantial
impairments potentially resulting in diminished therapy adherence as well as impaired quality of life. However,
evidence for the effectiveness of nurse-led interventions on symptom management and quality of life is still very
limited. This especially applies to care transitions between different inpatient and outpatient health care providers
throughout the course of treatment and aftercare.
Methods/Design: Supportive Cancer Care Networkers (SCAN) is a prospective randomized controlled trial conducted
in eight large and middle-sized German cancer centers and municipal hospitals. The target population is adults with
colorectal cancer UICC I-III after initial R-0 resection scheduled for adjuvant chemotherapy or guideline-based aftercare
only. 370 patients will be randomly assigned to either intervention or control group. Patients in the intervention group
will receive an additional support by specialized oncology nurses for eight weeks after discharge from hospital by
telephone, consisting of symptom monitoring, counselling on self-assessment and self-management and dealing with
individual resources for coping and psychosocial well-being. The primary endpoint will be health-related quality of life
(HRQoL) at eight weeks after discharge from the initial treating hospital.
Discussion: The presented SCAN trial is to provide information that will be useful to advance our understanding of
complex interdependencies between symptom severity, supportive care needs, functioning and the risk for
diminished HRQoL. Most importantly, these patient-reported outcomes are not fully implemented in today’s
clinical routine practice potentially resulting in therapy cessations and lower chemotherapy treatment rates
for colorectal cancer especially in older patients.
Trial registration: ClinicalTrials.gov Identifier NCT01651832.
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Colorectal cancer (CRC) is the second most frequent
malignant disease in Germany with 62,430 newly diag-
nosed cases in 2010, 5-year prevalence of 214,300 and
with more than 25,000 cases persistently the second
most frequent cause of cancer death [1]. During the past
decade, 5-year relative survival from colorectal cancer
increased to 65 %. Despite of effective primary preven-
tion, prevalence will continue to grow at over 3 % per
year [2]. Thus, a growing number of survivors of colo-
rectal cancer are likely to experience unmet supportive
care needs (SCN) during the course of treatment to a
different extent as well [3]. We are now questioning the
possibilities of covering those supportive needs properly
without exceeding personnel and financial resources.
Unmet supportive needs
Recently published studies revealed a significant share of
patients whose supportive needs are not covered entirely
within routine care practice today [4]. Unmet supportive
needs in turn have been proven to be significantly asso-
ciated with diminished health-related quality of life
(HRQoL). Such unmet supportive needs can refer to
either physical or psychological symptoms as well as
accessibility of health care or social welfare benefits.
Meeting these needs is likely to improve the patients’
quality of life by lowering symptom severity and psycho-
logical distress and might prevent dissatisfaction with
health care [5–8].
But, while the assessment of cancer or therapy-related
symptoms is more and more integrated into routine sup-
portive therapy, the assessment of SCN still lacks a sys-
tematic implementation [9–11]. An especially critical
phase in the course of treatment for not addressing the
patients’ supportive needs sufficiently is the transition
from in-patient primary therapy to out-patient aftercare
[12]. Especially in more than 30 % of elderly patients (65+)
chemotherapies are discontinued within 1–4 months due
to persistently high levels of symptoms and functional im-
pairments, leading to significantly diminished survival
[13]. Therefore, national and international guidelines on
the treatment of colorectal cancer recommend opti-
mizing treatment of side-effects and cancer-related
symptoms seamlessly [14–16]. Hence, a systematic
monitoring is necessary for the treatment of symp-
toms and impairments [16].
Recent reference data from the QUASAR2-trial [17]
proved that up to 30 % of patients suffer from substan-
tial therapy-induced symptoms during active therapy.
Depending on the regime, common toxicities in patients
with colorectal cancer are diarrhea, nausea and vomit-
ing, mucositis/stomatitis, myelosuppression, and hand-
foot syndrome. This may lead to avoidable impairments
in HRQoL as it is often found in patients with colorectal
cancer [18–20]. Moreover, the necessity for follow-up
treatment can last for years after initial diagnosis and
treatment as a recent analysis in long-term survivors in
the US with leukemia, bladder, and colorectal cancer
showed [21]. And even without being indicated to adju-
vant chemotherapy, patients in early tumor stages usu-
ally state increased psychosocial and medical supportive
needs, especially after surgery [22].
Nursing interventions to address SCN
In the past, nursing interventions for the improvement
of access to the care for cancer patients, for the support
in managing therapy-related side-effects, for the im-
provement of therapy compliance and care continuity
[23] as well as for the improved treatment management
have gained importance [10, 24–26]. The early detection
of therapy-related symptoms and functional restric-
tions by nursing staff can contribute particularly to
the improvement of outpatient aftercare and sustain
patients’ motivation for therapy compliance [17]. Add-
itional information on patients’ medical condition
using patient-reported outcomes (PROs) can contrib-
ute to support professionals involved in clinical deci-
sion making [25, 27].
Problem for cancer and other chronic diseases is the
fact that the medical condition as well as the resulting
supportive needs change during the course of the disease
and are hardly predictable [10]. That is why the routine
collection of relevant disease parameters and supportive
care need measures within integrated care concepts is
essential during the entire course of the treatment. We
were able to show that due to nursing interventions
symptom-related supportive care needs concerning dis-
ease- or treatment-related side-effects (nausea, vomiting,
pain, fatigue, malnutrition) can partially be addressed be-
yond inpatient treatment by conveying self-management
abilities and an attitude change in patients regarding
cancer [28–30].
In general, there is still a lack of nursing interventions
that cover unmet SCN of all different aspects during pri-
mary therapy and care transition. Random models have
been evaluated within clinical trials, such as e.g. patient
navigators, either based on nursing staff or lay persons.
Recently, special attention was paid e.g., on such guid-
ance throughout the course of treatment in a study by
Wagner et al. [31]. The Nurse Navigator program pro-
viding additional support regarding care access, distress
and fatigue assessment by telephone for 4 months was
compared to usual care. While patients in the Nurse
Navigator group stated improved experience and re-
duced problems in care access, the overall HRQoL was
not affected significantly. These findings might not be
standing in contrast to prior findings. As a study on the
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newly developed Comprehensive Concerns Assessment
Tool and the European Organization for Research and
Treatment of Cancer (EORTC) showed, the most im-
portant factors were related to self-management abilities,
psychological symptoms and medical information rather
than the usual suspects, i.e. pain or gastrointestinal
symptoms [32]. Furthermore, continuous access to
qualified health care providers and other resources for
the management of long-term debilitating symptoms is
essential from the patient’s view even for years after the
initial diagnosis and treatment [33]. There is preliminary
evidence for the feasibility and acceptance of an elec-
tronic monitoring of symptoms that could be useful for
clinical decision making, too [34]. Thus, it is to be as-
sumed that prior standardized interventions as men-
tioned above failed to address the entire variety of
changing unmet SCN in differing phases of the care
process sufficiently, leading to a possible mismatch
between the patient’s current condition and the support
provided. Following the state of research, in these sub-
jects a personalized approach as proposed in this paper,
can take on an important role. Moreover, our approach
is likely to add in-depth information on interdependen-
cies between different domains of SCN in order to facili-
tate the promotion of HRQoL effectively.
Objectives
The main purpose of this study is to increase the
proportion of patients achieving a clinical relevant
improvement of their health-related quality of life of
10pts. [35] by 15 % compared to usual care. Second-
ary objectives are to
1) Determine the prevalence, time of occurrence and
severity of unmet SCN,
2) Analyze effective elements of nurse-led patient
counselling on patient self-management,
self-assessment and knowledge,
3) Identify individual resources that medical
professionals can strengthen and utilize to build up
the patient’s autonomy and coping abilities and
4) Determine the effect of a supportive nurse-led




SCAN is a prospective randomized controlled multi-center
trial in adult patients with colorectal cancer (International
Classification of Diseases, ICD-10 C18-20) in Union inter-
nationale contre le cancer (UICC) stage I-III. The study is
conducted in the surgical wards of eight large and middle-
sized cancer centers and general hospitals in Saxony-
Anhalt and Saxony, Germany.
Patients randomly assigned to the intervention arm
receive additional support by specially trained oncology
nurses for eight weeks after discharge from hospital fol-
lowing surgical therapy. Allocation to either intervention
or control group is performed with equal ratio. The fol-
lowing amendments were submitted to the local ethics
committee and approved on June 4th 2013:
1.) Expansion of eligibility criteria to UICC stage I and
2.) Change of the primary outcome from adjuvant
chemotherapy utilization to HRQoL.
Both amendments are causally linked to one an-
other. Prior to the amendment only patients with
UICC stage II & III were eligible for trial inclusion
because of the actual medical guideline for the treat-
ment of colorectal cancer. According to this guideline,
adjuvant chemotherapy is indicated in patients with
UICC stage II and more advanced tumor states only.
Due to upcoming effects of the establishment of the
preventive colonoscopy as a standard benefit of the
German statutory health insurance a noticeable shift
regarding tumor stages is obvious. Studies, which
were published after approval of the study by the
sponsor show that colorectal cancer, despite of the
low participation rate of the healthy general popula-
tion is detected significantly more often in early
stages (UICC I) [36, 37] than previous reference data
suggested. Nevertheless, this positive effect leads to a
significant reduction of the patients eligible for the
study. With the additional inclusion of patients in the
UICC stage I a rise of the case number of approx.
40 % could be achieved. At the same time, patients in
UICC I are not indicated to adjuvant chemotherapy.
As a result, widening the eligibility criteria had to be
accompanied by changing the primary outcome. Since
HRQoL had been defined as a central secondary out-
come, the primary outcome was replaced by a former
secondary one without changing elements or proce-
dures of the intervention itself.
Study population
The target population is adult patients with colorectal
cancer (International Classification of Diseases, ICD-
10 C18-C20, UICC I-III) in curative therapy condi-
tions. Eligible patients will be identified after surgery
by hospital physicians through histological and patho-
logical findings. Eligible patients expressing interest in
taking part in the study will be contacted by a spe-
cially trained oncology nurse and an initial appoint-
ment will be scheduled. Fully informed written consent
will be obtained before collecting any data or providing
counseling.
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Inclusion criteria
 Being treated surgically at one of the participating
study centers for colorectal cancer (R0)
 Age 18–85 years.
 ECOG performance status 0–2
 Prospective further life expectancy of >3 months.
 Living in Saxony-Anhalt or Saxony.
 Ability to participate in regular follow-up intervals
as determined in the medical guideline
 Informed written consent must be obtained
according to ICH/EU GCP, before trial inclusion.
Exclusion criteria
 Contraindications for surgical therapy, according to
the medical guideline, e.g. Inadequate liver, bone
marrow, and kidney function or coronary heart
disease (NYHA III-IV).
 Lacking ability to understand, speak and write
German
 Being admitted to a nursing home permanently.
Primary endpoint
The effectiveness of SCAN program will be assessed on
an individual patient level by comparing the proportion
of patients who achieved a clinical relevant improvement
of their HRQoL by 10 pts. At 8 weeks after discharge
from hospital.
Secondary endpoints
An overview on primary and secondary endpoints and
the study timeline is provided in Table 1:
Sample size
For sample size calculation the portion of the patients
who reach a clinically relevant improvement of the glo-
bal health-related quality of life (HRQoL) within 8 weeks
after discharge from hospital is chosen. The sample size
calculation is based on an expected response difference
of 15% points in the subscale “global health status”/QoL
of QLQ-C30 EORTC between the intervention and the
standard treatment 8 weeks after the clinic dismissal
after surgical therapy. Own reference data [30] show a
response of 48 % in standard treatment, so that in the
intervention group responses of 63 % are expected. To
be able to detect a relevant effect of the intervention
with a rise of the responses by 15% points with 80 %
power, n = 370 patients (n = 185 patients per study
arm) are needed. Including a dropout rate of approx.
10 %, n = 406 patients (n = 203 per study arm) will be
recruited.
Randomization
Randomization on an individual level, patient enrollment
and group allocation will be performed by fax from the
Institute of Medical Epidemiology, Biostatistics, and In-
formatics (IMEBI), Halle as an external and independent
unit. Randomization will be stratified by center using
blocks of variable length from a reproducible SAS PROC
PLAN code. A consecutive analysis of non-responders
and of the causes for changes in therapy regimes is
intended additionally due to the high therapy-related
impairments in wellbeing and quality of life during adju-
vant chemotherapy.
Blinding
Patients are blinded for this study. A distinct patient
number is allocated in case of inclusion in the study. A
blinding of the medical staff (physicians, oncology
nurses) is impossible due to the frequent re-admission
of patients to be expected and the disclosure of informa-
tion in the patient-held records.
Study procedures
The study flowchart is presented in Fig. 1. The study
timeline is presented in Fig. 2.
Intervention
Feasible patients are assessed by the participating study
centers and registered to the coordinating trial center.
Patients meeting the inclusion criteria and signing a
Table 1 Outcome measures and measure times
Measure times T0 T1 T2
Outcomes & Instruments Baseline (day before
discharge)
Primary measurement
(8 weeks after discharge)
Follow-up (8 months
after discharge)
HRQoL (primary outcome) EORTC QLQ-C30 + EORTC-QLQ CR29 x x x
Utilization of adjuvant chemotherapy x (if appropriate) x
Supportive Care Needs and individual
resources
FU-T 37 x x
Distress Distress Thermometer (DT) x x
Symptoms and functional impairments MD Anderson Symptom
Inventory
x x
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written informed consent are randomized into the
study arms. Patients in the intervention group are of-
fered an additional nursing intervention after dis-
charge for 8 weeks. The intervention time-line was
adjusted to the actual S3-guideline on the treatment
of colorectal cancer regarding the recommended latest
onset of adjuvant chemotherapy. The intervention
consists of a standardized protocol-based telephone
follow-up serving once per week to disclose patients’
current supportive needs and in order to detect
therapy-related physical and psychological impair-
ments as early as possible. Standardized protocols
were developed beforehand to ensure both consistent
assessment and patient information during the coun-
seling. Additionally, the SCAN is at patients’ disposal
for contact from the beginning of primary therapy
during the inpatient stage to outpatient aftercare for
up to eight months. The intervention covers the en-
tire period of transition from acute clinical care to
out-patient aftercare.
Fig. 1 Study flowchart/CONSORT diagram
Fig. 2 Time line and procedures
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Training of the nursing staff
Incidents classified as critical were processed beforehand
by the research group into a telephone guideline. These
incidents and appropriate counseling facilities are in-
cluded in the training program prior to the implementa-
tion of the intervention. Specialist oncology nurses
designated to carry out the intervention underwent a
two-day training (a total of 18 h) conducted by clinical
oncologists and members of the study group.
In-patient period
Patients in the intervention group are visited twice by a
specially trained oncology nurse (Supportive Cancer
Care Networker, SCAN) during their inpatient stay. Both
visits take about 30 to 60 min. Fist, patients are given
relevant information, i.e. contact with specialists, volun-
tary services and the next steps and appointments of the
treatment plan on the second last day before discharge
from hospital. Second, at the last day before discharge
the SCAN takes up the contact information and ap-
points weekly telephone consultations for eight weeks.
Patients are handed out written information materials
and the study documents, as for example, patient-held
records (PHR), are explained. The PHR is derived from a
newly generated 37-item generic supportive needs ques-
tionnaire “Fragebogen zur Erfassung von Unterstützungs-
bedarfen von Tumorpatienten“(FU-T). To ensure that
patients are enabled to inform structured and completely
about relevant changes of their medical condition, filling
in the PHR is practiced under instructions. In coordin-
ation with the treating clinicians, critical events in which
an immediate contact to the SCAN should occur are
listed individually.
Out-patient period
During the outpatient intervention period the SCAN
inquires therapy-related symptoms and functional limi-
tations of patients regularly using patient-held records
(PHR) in order to assist patients during the transition
from inpatient acute care to outpatient aftercare. In the
first eight weeks after hospital discharge obligatory tele-
phone consultations are carried out by the SCAN. Dur-
ing the consultations the SCAN rates the urgency of
unmet supportive needs, incorporates qualified help if
necessary and supports communication of involved
health care professionals. Support is provided in five cat-
egories of possible supportive needs following standard-
ized protocols:
1) Proper self-management strategies for physical and
psychological symptoms
Patients stating persistent physical or psychological
symptoms are guided in effective self-assessment
possibilities. Moreover, depending on the kind of
symptom suitable self-management strategies are
discussed by the SCAN.
2) Warranty of care continuity
The entries in the PHR are discussed on the phone
with a SCAN regarding critical incidents. Here, the
individually determined critical events and processes
are forwarded to attending hospitals or resident
physicians in order to initiate treatments appropriate
to the occurring problems and to call in or hospitalize
patients. Additionally, patients have the possibility
to call between telephone appointments in case of
therapy-related complications and side-effects and
of psycho-oncological or logistic problems. An
early detection of therapy-related physical and
psychological impairments also aims at optimizing
treatment management by providing an almost
real time feedback to the medical professionals.
3) Informed decision making
Beginning at the in-patient consultations, detailed
information on the therapy plan as well as alternatives
is provided. Further information needs are addressed
during the appointed telephone calls, depending on
the occurrence of events in need for support, e.g.
pharmacological and non-pharmacological supportive
measures, or referred to qualified external health care
professionals and self-help groups.
4) Participation
In addition, within the entire out-patient intervention
period, patients are guided in access to office-based
oncology specialists and organizational or logistical
barriers to medical treatment facilities are discussed
with the SCAN. Furthermore, patients are actively
encouraged to keep a high therapy adherence,
especially in patients living in rural areas or the
socioeconomically deprived.
5) Psycho-social well-being
The consultation is aimed individually on the
patient. Counseling on psychological well-being
pursues an improvement of the quality of life by
the support of the psychic as well as the social
functionality of the patient, which is possibly a
prognostic factor for the overall survival [10, 27].
Thereby, special attention is paid to individual
resources of the patients. Patients are aided in
defining both useful individual and institutional
resources, e.g. experiences of self-efficacy or
available social security benefits.
Follow-up
In order to determine differences in healthcare services
utilization between intervention group and controls, all
patients are asked to fill out additional written question-
naires at 8 weeks and 8 months after discharge from
hospital. At both times, patient’s adherence to medical
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recommendations and completion of medical therapies
is assessed as well.
Potential adverse events
The SCAN intervention with a non-invasive educational
profile is considered to include no additional risk.
Removal from the study
Subjects may refuse to participate in the study at any
time without giving a reason. The following further rea-
sons can lead to withdrawal of the study for single
patients:
 Wish of the patient,
 non-compliance,
 Not the predictable health disturbances which force
the patient to the withdrawal, according to the
appraisal of the treating doctor,
 Death of the patient.
Statistics
Primary endpoint analysis
The analysis of the primary outcome will obey to the
intention-to-treat principle using generalized linear re-
gression modelling and reported as relative risk with its
according 95 % confidence interval. The model will be
adjusted for cancer site, tumor stage, cancer therapy,
ECOG performance status, age, sex and eventual previ-
ous neoadjuvant radiation therapies.
Secondary endpoint analysis
Secondary endpoints will be assessed by the respective
two-group tests with a corresponding 95 % confidence
interval. For each secondary endpoint specific statistical
tests will be conducted. That is, for continuous out-
comes the t-test will be used, for binary outcomes the
chi-square-test and for time-to event outcomes the log-
rank test. Secondary endpoint analyses are considered as
exploratory. Subgroup analyses will be undertaken by
checking interaction of covariates with intervention [38].
The trial will reported according to the guidelines of the
consolidated standards of reporting trials (CONSORT)
for randomized controlled trials. Adverse events will be
reported as rates with corresponding 95 % confidence
intervals. All adverse events (AEs) and serious adverse
events (SAEs) will be given in lists.
Supplementary qualitative analysis
Due to the large amount of free text data gathered in
the PHR, a supplementary qualitative analysis based on
the approach by Maying [39] will be carried out. It will
be based on a specific category system underlying the
incorporated FU-T questionnaire. Developing the final
categories therefore is performed inductively from the
material on the free text data by summary, explication
and structuring. The categories are defined and collected
together with demarcation rules and anchor examples in
a code-decode guide which forms the guideline for the
classification of passages. Based on this code-decode
guide the free text data are explored and re-categorized
if necessary. After the final production of category sys-
tem and code-decode guide the content will be rehashed
descriptively. These results are processed in graphical
representations.
Auditing
To realize quality assurance the Institute for Health and
Nursing Science as the coordinating center of the study
will provide an advanced support for documentation and
study management in the recruiting centers. Trained re-
search staff will visit each center at least 4 times. Pre-
study-visit (1): the practice team will be introduced into
the trial procedures, qualification of practice staff and
research capacities building and documentation will be
checked. Study visit (2 & 3): support for follow-up and
data management with special attention on reporting
AEs and SAEs. Post-study-visit (4): final query manage-
ment. Additional audits can occur at any time during or
after completion of the study. Monitoring will be per-
formed regularly by verifying key data (signed informed
consent form, inclusion and exclusion criteria and key
baseline data). The research staff will be trained in
source data verification and will be supported in prepar-
ing standardized reports.
To ensure the implementation of the intervention, qual-
ity audits are being conducted in the intervention groups
in all study centers based on the guidelines of the Royal
Collage of Nursing [40] and the German Network of
Quality Assurance in Nursing Care [41]. The audit is
based on (1) regular monitoring of the trained nurses’
knowledge about the training module, and (2) on an add-
itional comparison of nursing records with study docu-
mentation for 10 % of all included patients. Nurses who
administer the interventions and assess the outcomes are
aware of group allocation due to their participation in the
training to manage the SCAN intervention. Patients are
not informed about group assignment, but might be aware
of it due to unmasking information from nurses. Group
allocation perception of included patients will be assessed
at follow-up.
Ethical matters
The study is performed according to the ICH-GCP prin-
ciples and is approved by the local ethics committee of
the Medical Faculty at the Martin-Luther-University and
regional ethics committees of the participating centers.
The trial is registered in the clinical trial registry
ClinicalTrials.gov.
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Discussion
During the past two decades, nurse-led telephone-based
care coordination programs to improve outcomes such as
HRQoL after surgical resection for colorectal cancer have
gained increasing importance. However, nurse-led case
management concentrating on information provision and
care pathway supervision alone was not effective in pro-
moting HRQoL [19]. As reported by Gray et al. [42], there
are both modifiable and fixed factors predicting HRQoL.
Especially an effective management of symptoms, e.g.
anorexia, dyspnea, fatigue, depression and impaired activ-
ities, appears to be potential for interventions to improve
HRQoL in patients with colorectal cancer. Recently, a
qualitative analysis by Sun et al. [33] emphasized the
importance of a long-term coordination of care in order
to manage also persistent late-effects even for years after
initial diagnosis. To this issue, newer research proved that
an assessment of those symptoms is feasible and safe even
in real-time reporting systems carried out via cell phone
applications [43]. However, the available evidence is still
very limited. A systematic review of controlled trials con-
cluded that there is no clear evidence to date that unmet
needs are indeed modifiable due to methodological issues
and low statistical power or inadequate measures [44].
The Australian CONNECT study, e.g., with a compar-
able approach found no differences in unplanned re-
admission (25.6 % of interventions vs. 27.9 % of controls;
P = 0.5). In this study also no significant differences in
experience of care coordination, distress, or HRQoL be-
tween groups were achieved [45]. The authors concluded
that the intervention was probably not intensive enough
to be effective. Furthermore, the sample studies showed
low levels of SCN in general which stands in contrast to
prior findings from other studies in patients with colo-
rectal cancer [46].
In contrast to these findings, a Chinese study compar-
ing a self-efficacy enhancing intervention to standard
care found a coincident significant improvement in their
self-efficacy (F = 7.26, p = 0.003) with a reduction of
symptom severity (F = 5.30, p = 0.01), symptom interfer-
ence (F = 4.06, p = 0.025), anxiety (F = 6.04, p = 0.006)
and depression (F = 6.96, p = 0.003) at three and six
months [47]. However, no significant improvements in
HRQoL were observed. In addition, a longitudinal pro-
spective evaluation of toxicity conducted in the UK sug-
gested that nurse-led telephone follow-up can potentially
lead to reduced symptom severity (chest pain, vomiting,
oral mucositis, nausea, insomnia) and has a similar impact
on the management of some symptoms when compared
to home care [48].
The findings of the SCAN trial will facilitate the pro-
spective selection of individually appropriate strategies
in the trans-sectoral management of patients with CRC
and evaluate the effectiveness daily clinical routine.
The proposed SCAN trial, although targeting a similar
population as the trials mentioned above, is different in
several important aspects. First, we propose a more
comprehensive screening of occurring SCN throughout
the course of treatment. A previous trial [49] reported
that toxicity management was most effective within the
first two cycles of treatment. Afterwards, many symp-
toms are likely to reach a stable plateau. Taking these
findings into account for the SCAN intervention, the
critical time to provide supportive care interventions for
symptom management and HRQoL enhancement is not
only the first two weeks of chemotherapy, but also continu-
ously during routine aftercare in order to avoid prolonged
high levels of symptoms and functional impairments.
Second, the intensity of the study intervention is not
limited to a specific timeline only, but also to the pa-
tient’s needs for additional support. As Reese et al. [50]
recently showed, HRQoL, supportive needs as well as
functioning are not only interdependent but also re-
sulted in highly distinctive perceived illness burden.
Thus, the individualized real-time SCAN intervention
has the potential to meet the demands of subgroups of
CRC patients more targeted regarding supportive care
coordination and with it to alleviate upcoming illness
burden at an early stage.
Third, there is an ongoing debate on how to optimize
multi-professional care. An unsolved problem in routine
care settings today with potentially high relevance for
the proposed SCAN trial is the knowledge of the nursing
staff. Especially, insufficient knowledge of cancer sur-
vivor issues [51] and also a lack of feasible measures has
been shown to be an important barrier to providing
appropriate follow-up care [52]. Besides, nurses’ recogni-
tion may not accurately reflect the patients’ supportive
care needs in every aspect [53]. To eliminate this bias,
we offer an extensive training of the physician and nurs-
ing staff prior to implementation of the SCAN interven-
tion. This training will be incorporated continuously
throughout the trial conduction.
In summary, data from this study will contribute to
understanding the link between unmet SCN and the
risk for diminished QoL by providing a more in-
depth look into the individual perception of the dif-
fering importance of health and care-related problems
occurring over time.
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